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The correlation between endothelial function and reactive oxygen species detecting from diabetic microvascular wall and the
antioxidant eﬀect of ascorbic acid (AA) during early and late phases of diabetic induction were determined. Male Spraque-Dawley
rats were divided into four groups: control, diabetes rats (DM, using iv.injection of 55mg/kg BW streptozotocin, (STZ)), and two
groups of DM rats treated with AA (1g/L, (STZ)) starting on day 2 (DM + AAday2) and week 6th (DM + AA6wk). On 12th week
after STZ injection, the ﬁndings showed that in DM group, Ach (10−5 M)-induced vasodilatation was decreased, while the number
of leukocyte adhesion was increased signiﬁcantly (P<0.01). Interestingly, these abnormalities induced by DM could be protected
or improved in both AA-treated groups, DM + AAday2 and DM + AA6wk. By using dihydrorhodamine 123, our ﬁndings also
indicated that the existing of ROS productions on diabetic arteriolar and venular walls were diﬀerent signiﬁcantly (ROSarteriole =
165.89 ± 24.59 and ROSvenule = 172.26 ± 34.70) (P<0.05). Moreover by using BH4 inhibitor to induce increase in arteriolar ROS,
the results also conﬁrmed that AA could improve endothelial function with closed correlation to its potential to reduce vascular
ROS content.
1.Introduction
Theimbalancebetweenhyperglycemic-inducedreactiveoxy-
gen species (ROS) and antioxidative systems both enzymatic
and nonenzymatic appears to be a major factor contributed
to several diabetic complications [1–6]. In particular, it has
been suggested that the diabetes-induced oxidative stress is
a crucial factor contributing to endothelial cell dysfunction.
The potential of endothelial cell line both arteriolar and
venular vessels to produce NO depending on ﬂow-mediated
or other agonists is physiological signiﬁcance. Many studies
have shown close correlation between diabetes-induced ROS
and impairments of both endothelial functions at arterioles
and venules in the microcirculation. In both human and
animal diabetic models, two characters which are commonly
used as indicators of endothelial cell dysfunction are the
impairment of endothelium-dependent vascular relaxation
and the increase in leukocyte-endothelial cell interaction
[4–9]. Particularly, the decrease of nitric oxide (NO)
bioavailability is referred as the underlining cause of those
impairments [5, 9].
Interestingly, the supplementations of antioxidants, such
a sv i t a m i nCa n dv i t a m i nE ,h a v eb e e nu s e df o rp r o -
tecting endothelium against ROS damages [5, 10, 11].
However, there was no evidence demonstrated whether the
supplementation of ascorbic acid (AA) that could restore
the diabetes-induced endothelial dysfunction is associated
directly with its action particularly on diabetes-induced ROS
at the vascular wall of arterioles and venules. Therefore, the
present study was aimed to examine the correlation between
changes of endothelial function and microvascular wall ROS
content. The direct detection of microvascular wall ROS
content will be accessed by dihydrorhodamine 123 (DHR)
in the mesenteric arteriolar and venular walls of diabetes and
diabetes treated with AA groups.2 International Journal of Vascular Medicine
In order to conﬁrm the beneﬁcial eﬀect of ascorbic acid
on protecting endothelial function, the acute change in Ach-
responseafterpretreatedwithBH4-inhibitor,2,4-diamino-6-
hydroxy-pyrimidine (DAHP, Sigma-Aldrich Co., USA), was
further conducted in normal rat group. This experimental
DAHP-induced BH4 deﬁciency was set up in order to imitate
the condition of diabetes-induced endothelial dysfunction.
In addition, this kind of research ﬁndings could also lead
to the possible mechanism of how vitamin C could protect
diabetic endothelium.
2.MaterialsandMethods
2.1. Diabetic Induction. Male Spraque-Dawley rats (200–
250g) were purchased from the National Laboratory Ani-
mal Center, Salaya Campus, Thailand. Experiments were
conducted in accordance with the guidelines for experi-
mentation with animals of the National Research Council
of Thailand (1999) and approved by Ethical Committee,
Faculty of Pharmacy, Chulalongkorn University. Diabetes
wasinducedbyintravenousinjectionofstreptozotocin(STZ;
50mg/kg·B W )( S i g m aC h e m i c a lC o . ,U S A ) .T h ei n c l u s i o n
criteria for diabetic condition were the level of blood glucose
≥200mg/dL at 48 hours after the STZ injection. Control rats
were injected by the same volume of citrate buﬀer instead.
2.2. Experimental Protocol. The animals were divided into
four groups: control (CON), diabetic (DM), diabetic rats
treated with ascorbic acid (AA) starting on day 2 (DM +
AAday2)andon6weeks(DM+AA6wk)afterSTZinjection.
In DM + AAday2, and DM + AA6wk groups, AA (99%
L-ascorbic acid, Sigma Chemical Co., USA) was started to
administer in drinking water (1g/L) on 2 days and 6 weeks
after STZ injections, respectively.
2.3. Microscopic Observation of the Mesenteric Microcircula-
tion. The rats were anesthetized with sodium pentobarbital
(50mg/kg·BW, iv). The mesenteric microvasculature was
observed using ﬂuorescence videomicroscopy. A chamber
was placed under the distal ileum mesentery, which was
superfused continuously with Krebs–Ringer buﬀer solution
(pH 7.4,2mL/min, 37◦C) and covered with buﬀer-soaked
gauze to prevent tissue dehydration. Mesenteric microcir-
culation was observed by ﬂuorescence videomicroscopic
system (Optiphot 2, Nikon, Japan) equipped with a 100W
mercury lamp, real-time CCD camera (C2400, Hamamatsu
Photonics, Japan), a video recorder (VC-S5, Sharp, Japan)
with a video timer (VTG-33, For-A, Japan), and a 20x
objective lens (CF Plan Fluor, Nikon, Japan). Fluorescein
isothiocyanate labeled dextran (FITC-Dx-250; MW 250,000,
Sigma-Aldrich Co, USA) (5μg/mL) and acrdine orange
(Sigma-Aldrich Co, USA) (25μg/mL) were injected intra-
venouslyforvisualizingthemesentericmicrovasculatureand
thebehaviorofleukocytesinmicrovessels,respectively[4,7].
2.4. In Vivo Assessment of ROS Using DHR. To quantify the
amount of ROS located at the vascular walls of selected
mesenteric area, the superfusion of 0.1mL/min dihydrorho-
damine 123 (DHR, Sigma Chemical Co., USA) (10μmole/L)
was used and recorded by intravital ﬂuorescence videomi-
croscopy. DHR, an oxidant-sensitive ﬂuorescent probe, was
used to measure ROS generation in vivo. This method
has been previously validated by diﬀerent authors [12–
15]. Oxidation of DHR primarily by hydrogen peroxide-
dependent reactions forms rhodamine 123, which ﬂuo-
resces. The amount of formed rhodamine 123 was followed
by excited wavelength, 488nm, and emission wavelength,
525nm, respectively [12–14]. Images of 512 × 512 pixels
were acquired by 20x objective lens. Using a digital image
software (Image Pro Plus; Media Cybernetics, Inc, USA), the
rhodamine 123 ﬂuorescence intensity of each small window
located along the 100-μm length of arterioles (15–30μm)
and venules (20–30μm) were determined. The averages of
intensities of 14 windows (100-μm length) was determined
for background intensity (0min before DHR superfusion,
Ibase) and for 1-min intensity (I1min) after DHR superfusion.
The percentage of ROS change was then presented by the
following:
%c h a n g eo fR O S−associated ﬂuorescent intensity
=

I1min−
Ibase
Ibase

×100.
(1)
2.5. Measurement of Biochemical and Physiological Param-
eters. T h ea r t e r i a lb l o o dp r e s s u r ew a sm e a s u r e dv i aa
canula inserted into the carotid artery using a pressure
transducer (Nikhon Koden, Japan). Blood glucose, plasma
AA, and glycosylated hemoglobin (HbA1C) were determined
in blood sample collected at the end of each experiment.
Blood glucose was determined using a glucometer (Advance
Glucometer, Boehringer Mannheim, Germany). The HbA1C
was analyzed using colorimetry (Bangkok RIA lab Co,
Thailand). The plasma AA was measured using enzyme-
assisted spectrophotometry (Research Center, Ramathibodi
Hospital, Mahidol University, Thailand).
2.6. Measurement of Vascular Function. Two diﬀerent
vasodilators, acetylcholine (Ach; 10
−5 M) and sodium
nitroprusside (SNP; 10
−5 M) were used to examine the
endothelial-dependent and -independent vasodilatation
responses of mesenteric arterioles (15 to 30μm in diameter).
Changes of arteriolar diameters were determined by oﬀ-line
image analysis (Image Pro Plus; Media Cybernetics, USA),
based on the ﬂuorescence images recorded 5 minutes after
the topical application of each vasodilator and expressed as
the percentage changes (%) from the baseline values (NE-
pre-constricted (NE; 10
−5 M)).
2.7.MeasurementofNumberofAdherentLeukocytes. Inorder
to assess the number of leukocyte adherence, the mesenteric
tissues were prepared similarly to that described earlier.
Instead of using FITC-dextran 250, 0.3mL rhodamine 6G
(conc. 0.3mg/mL; Sigma, St. Louis, USA), a total of 0.09mg
rhodamine per animal, was injected into the rat’s jugular
vein [9]. Based on the rhodamine video images of eachInternational Journal of Vascular Medicine 3
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Figure 1: Experimental protocol for measuring ROS content and vascular response to Ach (acetylcholine) as the eﬀect of AA (ascorbic acid)
and/or 6R-BH4 (6R-5,6,7,8-tetrahydro-L-biopterin dihydrochloride) application after inhibiting BH4 biosynthetic by DAHP (2,4-diamino-
6-hydroxypyrimidine). There are four groups: control (CON + vehicle), control treated with DAHP (CON + DAHP), control treated with
DAHP with ascorbic acid (CON + DAHP + AA), and control treated with DAHP with ascorbic acid and BH4 (CON + DAHP + AA + BH4).
experiment,wecountedthenumberofleukocytes(N)whic h
adhered to mesenteric venules (20–30μm in diameter) and
remained stationary for more than 30 seconds. The number
of leukocyte adhering was counted by using the software
Global lab image II. Cn, cells/100μml e n g t hof venule,w a s
determined by the following:
Cn =
N
L
×100, (2)
where N is the total number of adherent leukocytes and L is
the venular length (μm) under the measurement.
2.8. To Conﬁrm the Antioxidative Eﬀect of Ascorbic Acid on
Endothelial Function. This study was performed by using
2,4-diamino-6-hydroxypyrimidine (20mM; DAHP, Sigma-
Aldrich Co., USA), 6R-5,6,7,8-tetrahydro-L-biopterin dihy-
drochloride (0.1mM; 6R-BH4, Sigma-Aldrich Co., USA),
and 2.6mM L-ascorbic acid (Sigma-Aldrich Co., USA).
DAHPisacompoundthatreducesintracellularBH4 levels.It
is a selective, speciﬁc inhibitor of GTP-CH 1, a rate limiting
enzyme for de novo BH4 synthesis [16–18].
In our experiment, we used 6R-BH4 as a positive control,
which is a compound for increased intracellular BH4 [19].
The 6R-BH4 is a cofactor for eNOS and binds to the enzyme
at a ratio of 1:1 BH4 :eNOS[20].
The rats were separated into four groups: control (CON
+ vehicle), control treated with DAHP (CON + DAHP),
control treated with DAHP with ascorbic acid (CON +
DAHP + AA), and control treated with DAHP with ascorbic
acid and BH4 ( C O N+D A H P+A A+B H 4).
To inhibit intracellular BH4 levels, we applied DAHP
(20mM; 1mL/5min for 30min), in order to diminish NO
production. In the presence of DAHP, vascular response
to Ach (10μM; 1mL/5min) was obtained after applica-
tion of AA (2.6mM; 10mL/1min) plus 6R-BH4 (0.1mM;
1mL/5min for 10min). Moreover, the arterial ROS content
wasalsodetectedusingDHR-ﬂuorescentprobe(dihydrorho-
damine 123 Sigma Chemical Co., USA) (10μmole/L) as well.
T h ee x p e r i m e n t a lp r o t o c o lo fe a c hg r o u pw a ss h o w ni n
Figure 1.
2.9. Statistical Analyses. A l ld a t aw e r ee x p r e s s e da sm e a n s±
SE. One-way analysis of variance with Tukey’s Post Hoc
test was used to compare between mean values. Signiﬁcant
diﬀerencewasconsideredbyaprobability(P-value)lessthan
or equal to 0.05.
3. Results
3.1. Biochemical Parameters and Physiological Characteristics.
The intravenous injection of STZ (50mg/kg·BW) caused
pancreatic islet cells to damage, resulting in hyperglycemia
within 48 hours. The hyperglycemia maintained throughout
the 12-weeks period of experiment. Loss of body weight was
observed in all of three DM groups, DM, DM + AAday2, and
DM + AA6wk, as compared to their aged-match controls.
In both DM + AAday2, and DM + AA6wk groups, the
blood glucose and HbA1C were not signiﬁcantly diﬀerent
when compared to the DM rats, while AA supplementation
increasedthebodyweightsigniﬁcantly(P<0.001)(Table 1).
Plasma AA level was reduced signiﬁcantly in DM group4 International Journal of Vascular Medicine
Table 1: Means ± SE of blood glucose (BG), HbA1C, body weight (BW), plasma ascorbic acid (Plasma AA), mean arterial blood pressure
(MAP) were demonstrated for 12 weeks of experimental periods control, DM, DM + AAday2, DM + AA6wk.
Group BG (mg/dL) HbA1C (%) BW (g) Plasma AA (mg/dL) MAP (mmHg)
Control 93.13 ±7.70
(n = 8)
3.68 ±0.54
(n = 6)
425.67 ±4.46
(n = 9)
1.30 ±0.15
(n = 6)
97.22 ±6.68
(n = 8)
DM 418.33 ±17.24∗
(n = 9)
10.86 ±0.24∗
(n = 7)
182.70 ±7.87∗
(n = 10)
0.62 ±0.02∗
(n = 7)
113.54 ±3.16∗
(n = 9)
D M+A A d a y 2 380.13 ±18.61
(n = 8)
9.81 ±0.30
(n = 8)
228.00 ±15.18
(n = 9)
0.99 ±0.03#
(n = 5)
92.70 ±6.47#
(n = 8)
DM + AA6wk 407.80 ±28.8
(n = 5)
10.34 ±0.35
(n = 5)
283.75 ±22.65
(n = 6)
1.27 ±0.04#
(n = 5)
95.33 ±6.90#
(n = 7)
∗P<0.001, signiﬁcant diﬀerence compared to control.
#P<0.001, signiﬁcant diﬀerence compared to DM.
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Figure 2: Percentage relaxation to Ach 10
−5 M and SNP 10
−5 M in control (CON), diabetes (DM), diabetes treated with vitamin C (1g/L)
starting on day 2 (DM + AAday2) and on 6 weeks (DM + AA6wk) after STZ injection. Values are mean ± SEM, CON: n = 9, DM: n = 7,
D M+A A d a y 2 :n = 7, DM + AA6wk: n = 6.
∗P < 0.001 versus CON, #P < 0.01 versus DM.
as compared to the controls. However, this reduction did
not appear in both DM + AAday2 and DM + AA6wk
groups (Table 1) .T h em e a na r t e r i a lb l o o dp r e s s u r e( M A P )
was increased in DM group. The increase in MAP was
attenuated signiﬁcantly with AA supplementation in both
DM + AAday2 and DM + AA6wk groups (P<0.001)
(Table 1).
3.2. Eﬀe c to fA s c o r b i cA c i do nV a s c u l a rF u n c t i o n .Figures
2(a) and 2(b) showed the percentage changes of arteriolar
diameters after relaxing by Ach and SNP in control, diabetes
rats without and with AA supplementation. It is to be
noted that AA supplementation prevented and restored the
endothelium-dependent vasodilatation, but not for the SNP
vasodilatation.
3.3. Eﬀe c to fA s c o r b i cA c i do nL e u k o c y t e s - E n d o t h e l i a lC e l l
Interaction. Figure 3 showed the number of leukocyte adhe-
sion in CON, DM, DM + AAday2 and DM + AA6wk groups.
Theiradherent-leukocytedensitieswerechangedfrom9.17±
1.45 cells/100μmi nD Mg r o u pt o4 .71 ± 0.43 cells/100μm
i nD M+A A d a y 2g r o u pa n dt o2 .15 ± 0.31 cells/100μmi n
DM + AA6wk group, respectively. Interestingly, the number
of leukocyte adhesion was decreased signiﬁcantly by both
intervals of AA supplementation.
3.4. Eﬀe c to fA s c o r b i cA c i do nD i a b e t e s - I n d u c e dR O SP r o d u c -
tion. Figure 4 showed the changes in the ROS-dependent
ﬂuorescence intensities detected from the rat mesenteric
arterioles and venules of each group at 0 and 1 minute after
DHR-123 superfusion. It was observed that DM showed the
strongly increased ﬂuorescence intensity as early as 1min
after DHR-123 superfusion. The changes in ﬂuorescence
intensities from CON, DM, DM + AAday2, and DM +
AA6wk groups after 1-min DHR superfusion were analyzed
using digital image analysis as described in methodology
above. The averages ROS contents determined from both
vascular walls of each group (CON, DM, DM + AAday2, and
DM + AA6wk) were summarized in Table 2. These ﬁndings
indicated that early AA supplementation as well as delayed
supplementationofAAcouldsimilarlyattenuatetheincrease
in ROS generation at both sites of microvascular walls.International Journal of Vascular Medicine 5
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Figure 3: Number (Cn) of leukocyte adhesion in control (CON),
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injection. Values are mean ± SEM, CON (n = 8), DM (n = 6), DM
+A A d a y 2( n = 7), and DM + AA6wk (n = 7).
∗P < 0.001 versus
CON, #P < 0.01 versus DM.
Interestingly, our ﬁndings also indicated that the existing of
ROS productions on diabetic arteriolar and venular walls
(Table 2)w e r eR O S arteriole = 165.89 ± 24.59 and ROSvenule =
172.26 ± 34.70. (P<0.05).
3.5. Correlations between Arteriolar ROS Generation versus
Vasodilatation and Venular ROS Generation versus Leukocytes
Adhesion. Figures 4(a) and 4(b) are plotted between arterio-
lar and venular ROS productions against Ach-vasodilatation
(results in Figure 2(a)) and number of leukocyte adhesion
(results in Figure 3), respectively. By using Pearson correla-
tion and linear regression analysis, the relationships between
those two parameters of each group were determined as
follows:
Arteriolar wall:
ya =− 0.101xa +1 6 .68

R2 = 0.99,P<0.02

(3)
Venular wall:
yv = 0.044xv +1 .29

R2 = 0.96, P<0.018

,( 4 )
where ya and yv are % change of arteriolar diameter
in response to Ach, and number of leukocyte adhesion,
respectively. xa and xv are % change of ROS contents in
arteriolar and venular walls, respectively.
3.6.TestingtheEﬀectofAscorbicAcidonProtectingEndothelial
Function Using DAHP and the BH4-Inhibitor. The results
showed in Table 3 indicated that the ROS-dependent ﬂu-
orescence intensity was signiﬁcantly increased when BH4
synthesis was blocked by DAHP in relation to CON + Veh
group (DAHP-treated CON = 169.61 ± 6.46% and CON
+V e h= 54.48 ± 14.90%, resp.). Whereas the enhanced
Table 2: Means ± S.E. of changes in DHR ﬂuorescence intensities
along the arterioles and venules. Values are means ± SE of each
group, CON (n = 5), DM (n = 5), DM + AAday2 (n = 6), and DM
+ AA6wk (n = 5), calculated by using the equation of: % change of
ROS-associated ﬂuorescent intensity = (I1min−Ibase/Ibase) × 100.
Group % change of ROS
in arteriolar wall
% change of ROS
in venular wall
Control 34.08 +15.62 38.31 +18.71
DM 165.89 + 24.59∗ 172.26 ±34.70
∗,a
D M+A A d a y 2 3 2 .86 +14.56# 49.59 ±21.26#
DM + AA6wk 26.02 + 8.03# 49.91 ±20.10#
∗P<0.001, signiﬁcant diﬀerence compared to control.
#P<0.001, signiﬁcant diﬀerence compared to DM.
aP<0.05, signiﬁcant diﬀerence between ROS contents in arteriolar wall and
venular wall in DM group.
ROS content was signiﬁcantly decreased in AA and 6R-BH4
t r e a t e dg r o u p s( C O N+D A H P+A A+B H 4 = 33.89 ±
7.62%, resp.). Moreover, AA in combination with BH4-
treated group showed synergistic increase in Ach-induced
vasodilation when compared to CON + DAHP. By using
Pearson correlation and linear regression analysis, the rela-
tionship between ROS-dependent ﬂuorescence intensity and
Ach-response can be described by the linear equation: y =
−0.097x + 23.45; R2 = 0.61, as shown in Figure 5.
4. Discussion
The results showed in Tables 1 and 2 demonstrated that
diabetes promoted the elevations of blood glucose, HbA1C,
and mean arterial blood pressure. Whereas, the depletion
of plasma vitamin C was showed with the increased
vascular ROS-sensitive DHR-123 intensities. The results of
ROS-sensitive ﬂuorescent probe indicated that there were
approximately 4.9- and 4.5-fold increased ROS contents in
the diabetic arteriolar and venular walls with respect to
the control values, respectively (Table 2). The ROS-sensitive
ﬂuorescent probe DHR-123 could speciﬁcally detect in vivo
ROS and was used successfully by several other mesenteric
studies [12–14] .I no u rs t u d y ,t h er e a lt i m ev i d e oi m a g e s
of mesenteric arteriole and venule which were superfused
by DHR-123 elicited that 12-wk diabetic mesenteric venular
wall provoked more ROS-sensitive ﬂuorescent intensity sig-
niﬁcantly than arteriolar wall (P<0.05). But this diﬀerence
did not occur in other experimental groups. Besides, this
increased ROS contents existed at the same stage where the
increased number of leukocyte adherence was encountered.
Therefore, it may implicate that the signiﬁcant increased
number of leukocyte adherence on 12-wk DM venules might
be the secondary source of ROS generation, particular via
the NADPH oxidase, and then caused more ROS-associated
ﬂuorescent intensity on venular wall than diabetic arteriolar
wall.
In addition, when the correlation between ROS contents
and vascular function was examined, our ﬁndings shown
in Figures 4(a) and 4(b) indicated that the relationships of
those parameters were signiﬁcant (P<0.02). The results
indicated that: (1) the negative correlation between the6 International Journal of Vascular Medicine
Table 3: Percentage changes of ROS (intensities/100-μm arteriolar length) and arteriolar diameters in response to Ach from mesenteric
arterioles in the presence or absence of BH4 synthetic inhibitor (DAHP, 20mM), DAHP plus AA, and DAHP plus BH4 donor (0.1mM) in
combination of vitamin C in control (CON) rat group.
Group
% changes of ROS
(intensities/100-μm arteriolar length) % changes of arteriolar diameters
6-wks CON
CON + Vehicle 54.48 ±14.90
(n = 4)
13.22 ±1.24
(n = 8)
CON + DAHP 169.61 ±6.46∗∗∗
(n = 4)
4.34 ±0.78∗∗∗
(n = 7)
CON + DAHP + AA 115.66 ±10.96aaa
(n = 3)
17.98 ±1.42aaa
(n = 6)
CON + DAHP + BH4
0.1mM + Vit. C
33.89 ±7.62aaa
(n = 3)
22.10 ±1.41aaa
(n = 6)
Values are mean ± SEM.
∗∗∗P<0.001, signiﬁcantly diﬀerence compared to 6-wk vehicle.
aP<0.05, aaaP<0.001, signiﬁcantly diﬀerence compared to 6-wk DAHP.
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Figure 4:PercentageofchangedDHRintensitiesandnumber(Cn)ofleukocyte-endothelialcellinteractionineachgroupofcontrol(CON),
diabetes(DM),diabetestreatedwithvitaminC(1g/L)startingonday2(DM+AAday2),andon6weeks(DM+AA6wk)afterSTZinjection
was plotted. The correlation and regression line were obtained for each group as demonstrated in (a). In (b), the correlation and regression
line were obtained for combined data of every group.
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Figure 5: The correlation and regression line between percentage
changesofROS(intensities/100-μmarteriolarlength)andarteriolar
diameters in response to Ach from mesenteric arterioles in the
presence or absence of BH4 synthetic inhibitor were obtained when
combined the data of every group.
ROS generation and vasorelaxation was obtained by the
linear line, ya =− 0.101xa + 16.68 (R2 = 0.99, P<
0.02); where, (2) the positive correlation between the ROS
production and leukocyte adhesion was demonstrated by the
linear line, yv = 0.044xv +1 .29(R2 = 0.98,P<0.018).
The idea was that vascular reactivity has a linear reverse-
correlation with arteriolar-wall ROS content. In contrast,
leukocyte adherence has a linear correlation with venular-
wall ROS content. Several studies [4, 5, 7–9] have indicated
that chronic hyperglycemia increased oxidative stress was
the major underlining cause which contributed to the
impairment of endothelial functions or called endothelial
dysfunction(ED).Similartoourstudy,EDwascharacterized
by the results of endothelium-dependent vascular relaxation
and the leukocyte-endothelium interaction (Figures 2-3).
Interestingly, our ﬁndings have also demonstrated that
diabetes-induced ED could be either prevented (the results
of DM + AA2day) or improved (the result of DM +
AA6week) by vitamin C supplementation. Therefore, theseInternational Journal of Vascular Medicine 7
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Figure 6: The diagram represents the proposed mechanism of ascorbic acid (AA) in attenuating reactive oxygen species (ROS) production
when DAHP inhibited BH4 and caused eNOS uncoupling. Similar to diabetic-induced endothelial cells dysfunction in associated with BH4
deﬁciency.
ﬁndings implied that as long as AA could diminish diabetes-
induced ROS content, the activity of endothelium was able
to be restored, probably via the maintenance of nitric oxide
(NO) bioactivity. Endothelial nitric oxide (NO) bioactivity
has a crucial role on both vascular sites, since, NO is
able to regulate both endothelium dependent vasorelaxation
and suppressing adhesive molecules expression [21–25].
The previous report using NO ﬂuorescent indicator, DAF-
2DA, has shown this beneﬁt of AA supplementation on
increased NO bioavailability as well [26]. However, the exact
mechanisms between roles of antioxidant and consequent
inﬂammatory process-derived-ROS production still need to
be clariﬁed.
Several studies indicate a close correlation between
BH4 bioavailability and eNOS function. Particularly, in
diabetes the reduction of bioavailability of BH4 promoted
eNOS uncoupling which contributes to further reduced NO
bioavailability and generates O2− and/or H2O2 rather than
NO.
In recent study, they found a signiﬁcant reduction
of intracellular BH4 levels after challenging endothelial
progenitor cells (EPCs) with high glucose concentration,
whereas, oxidized BH2 levels signiﬁcantly increased [27].
Consistent to the previous study by Sinozaki et al., 1999,
they showed that high fructose-fed rats enhanced formation
of O2−, which was caused by relative deﬁciency of BH4
and elevation of BH2 levels in aortic tissue [28]. Based
on this review, it is hypothesized that diabetes-induced
ROS could be related to the deﬁciency of BH4 by O2−
oxidation, resulting in enhanced BH2 (BH4 +O 2−→BH2
+H 2O2). Therefore, we conducted the further study by
using BH4 synthetic inhibitor, DAHP, in order to imitate the
diabetic rat model. As shown in Table 3, the 30-min DHAP
administration, the ROS-dependent ﬂuorescence intensities
were signiﬁcantly increased up to ∼3.1 time when compared
to CON+veh group. Whereas the combination of BH4 and
AA (DAHP+BH4+A A - t r e a t e dC O Ng r o u p )c o u l dd e c r e a s e
ROS intensity as much as 80% of CON+DAHP group.
Besides, the percentage changes of arteriolar diam-
eters after Ach application could increase signiﬁcantly
after BH4+AA-treated. In addition, our ﬁndings shown
in Figure 5 indicated that the relationships between ROS
contents and vascular function could be represented by a
linear equation; y = −0.097x+23.45 (R2 = 0.61). Therefore,
it might conclude that vitamin C can improve the uncoupled
eNOS and enhance its enzymatic activity as demonstrated
by increased Ach-induced vasodilation which was associated
with the decreased ROS contents, Since vitamin C could
reduce the BH2 to regenerate BH4 by the following action:
HO-ASC-OH + BH2 → O = ASC = O+B H 4 [28–31].
At this point, it may be suggested that in the situation
of DAHP-induced BH4 deﬁciency, eNOS uncoupling is
producedasitwillgenerateO2−andconsequentlyconvertto
H2O2− as demonstrated by DHR-123 detection. In addition
when eNOS uncoupling, less of NO is produced, there-
fore, the Ach-induced vasodilatation becomes signiﬁcantly
decreased in CON + DAHP group. In Figure 6, this idea
is summarized and presented for supporting the beneﬁcial
mechanism of vitamin C on protecting endothelial function
against oxidative stress condition.
At present, a number of human researches have focused
on preventing diabetes-induced cardiovascular complica-
tionsusingantioxidantssuchasvitaminsB,C,andE.Astheir
known superoxide scavenger properties, vitamins C and E
havebeenwidelyinvestigatedeitheraloneorincombination.
However, the beneﬁcial eﬀects of vitamin E supplementation
in surrogate measurements of cardiovascular disease in dia-
beticshavenotshownanyclearresults[32–34].Astudyfrom8 International Journal of Vascular Medicine
our unit, which included both types I and II diabetic patients
treated with a high dose of vitamin E (1,800IU daily) for 12
months, found no improvement in endothelial-dependent
or-independent vasodilation in both skin microcirculation
and brachial artery microcirculation tests. [33] In addition,
left ventricular function was not aﬀected by vitamin E
supplementation. In other word, vitamin C is also thought
to be involved in recycling the α-tocopheryl radical back to
α-tocopherol [35].
In conclusion, our ﬁndings have provided the in vivo
evidences for the fact that the abnormality of endothelial
cell observed in DM rats is signiﬁcantly in relation to the
ROS generation in microvascular walls. In particular, our
ﬁndingshaveindicatedthatmicrovascularROScontentseem
to be a major indicator for the progression of diabetes-
induced endothelial dysfunction. Therefore, the reduction
of microvascular ROS content by antioxidant like vitamin C
may be a valuable therapeutic approach in preventing and
reversing diabetic-induced microvascular dysfunction.
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